Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day

Shares of Supernus Pharmaceuticals (NASDAQ: SUPN), a developer of drugs that target diseases of the central nervous system, plunged as much as 19% during Tuesday's trading session following the release of its third-quarter operating results after the closing bell on Monday. While the company's third-quarter report looked stellar on paper, cost concerns and a possible guidance misunderstanding appears to be the root cause of today's damage.

For the quarter, Supernus reported $78.1 million in net product and sales, representing a 40% increase from the prior-year period. Trokendi XR, a treatment for migraine and epilepsy, did most of the heavy lifting with a 48.4% increase in total prescriptions written, while Oxtellar XR delivered a 10.1% increase in prescriptions written during the third quarter. Total sales, which included $2 million in royalty revenue and $0.3 million in licensing revenue, were $80.4 million.

Image source: Getty Images.

Source: Fool.com